Evidence map›Paper›PMID 41134994›Full record

ArticleJournal of Alzheimer's disease : JAD2025

Early branched-chain amino acid reduction delays the onset of cognitive decline in a mouse model of Alzheimer's disease.

Caitlyn A Mullins, Ritchel B Gannaban, Alyssa Kramer, Harsh Shah, Zobayda Farzana Haque, Marjan Ramezan, Fereshteh Dehghani, Arun Kumar Palaniyappan, Frances Bowers, Sheba Mj MohanKumar and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Caitlyn A MullinsNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Ritchel B GannabanNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Alyssa KramerNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Harsh ShahNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Zobayda Farzana HaqueNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Marjan RamezanNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Fereshteh DehghaniNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Arun Kumar PalaniyappanDepartment of Veterinary BioSciences and Diagnostic Imaging, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Frances BowersNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.
Sheba Mj MohanKumarDepartment of Veterinary BioSciences and Diagnostic Imaging, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Puliyur S MohanKumarDepartment of Veterinary BioSciences and Diagnostic Imaging, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Andrew C ShinNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, USA.ORCID 0000-0002-4748-5135

Funding

Branched-chain amino acids as a novel biomarker and treatment for Alzheimer's diseaseR21AG069140 · NIA · TEXAS TECH UNIVERSITY · PI HEGDE, VIJAY KARKAL, SHIN, ANDREW CHANGHUN · 2020 to 2020
$415k
Nanoparticles for detecting noradrenergic neurons in Alzheimer's DiseaseR41AG069539 · NIA · S G ENDOCRINE RESEARCH LLC · PI MOHANKUMAR, PULIYUR · 2020 to 2020
$267k
NIA NIH HHS R21 AG069140NIA NIH HHS R41 AG069539
6 · The paper itself

Abstract

BackgroundMany Alzheimer's disease (AD) treatments focus on a single variable of AD that have yet demonstrated clinically meaningful and perceived benefits by the patients. We recently showed that lowering plasma branched-chain amino acids (BCAAs) can deliver multiple pro-neuronal effects in APP/PS1 and 5xFAD mouse models.ObjectiveThe main aim was to determine the optimal point in time for the disease-modifying effects of BCAA reduction during AD development.Methods12-month-old, cognitively impaired male WT and APP/PS1 mice were injected with either vehicle or BCAA-lowering compound BT2 (40 mg/kg/day ip) for 30 days. To test if early BT2 during AD progression would have long-lasting beneficial effects, 2-month-old, cognitively intact male 5xFAD mice were treated with BT2 after which they were left alone for a month.ResultsPlasma BCAAs were reduced in BT2-treated APP/PS1 mice. Despite Aβ

Indexed as

Alzheimer DiseaseAmino Acids, Branched-ChainCognitive DysfunctionAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalMaleMiceMice, TransgenicAmino Acids, Branched-ChainAmyloid beta-PeptidesAmyloid beta-Protein Precursor5xFADAlzheimer's diseaseAPP/PS1BT2glycemic controlneurotransmitters

Identifiers

PMID41134994
PMCPMC12866969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.